Skip to main content
Insights into Imaging

Table 1 Baseline characteristics of the study population

From: Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines

Variable

Entire cohort

CTRCD (−)

CTRCD (+)

value

(N = 1151)

(N = 1049)

(N = 102)

Age at cancer diagnosis, years old

51.31 ± 9.10

51.17 ± 8.96

52.75 ± 10.34

0.139

Height, cm

162.46 ± 4.58

162.48 ± 4.53

162.27 ± 5.00

0.663

Weight, kg

57.72 ± 7.49

57.67 ± 7.46

58.26 ± 7.86

0.442

Heart rate, beats/min

68.03 ± 6.93

68.07 ± 6.96

67.54 ± 6.65

0.457

Systolic pressure, mmHg

119.08 ± 10.64

118.99 ± 10.73

119.92 ± 9.71

0.403

Diastolic pressure, mmHg

75.90 ± 7.63

75.89 ± 7.64

76.02 ± 7.48

0.868

Dyslipidemia, n (%)

52 (4.52)

47 (4.48)

5 (4.90)

0.845

TG

1.62 ± 1.32

1.63 ± 1.35

1.50 ± 0.95

0.332

TC

4.91 ± 1.04

4.90 ± 1.02

4.94 ± 1.20

0.722

HDL

1.57 ± 0.38

1.58 ± 0.38

1.51 ± 0.35

0.061

LDL

2.73 ± 0.81

2.72 ± 0.80

2.80 ± 0.85

0.365

ALT

25.21 ± 23.44

25.07 ± 23.18

26.67 ± 26.06

0.510

AST

27.97 ± 29.23

27.66 ± 29.23

31.21 ± 29.16

0.241

FBG

4.85 ± 0.64

4.86 ± 0.64

4.83 ± 0.61

0.659

Histologic type

   

0.981

Invasive ductal carcinoma

975 (84.71)

888 (84.65)

87 (85.29)

 

Invasive lobular carcinoma

114 (9.90)

104 (9.91)

10 (9.80)

 

Intraductal papillary carcinoma

47 (4.08)

45 (4.29)

2 (1.96)

 

Mucinous carcinoma

10 (0.87)

7 (0.67)

3 (2.46)

 

Other

5 (p 0.43)

5 (0.48)

0 (0)

 

Clinical stage

   

0.156

I

174 (15.12)

158 (15.06)

16 (15.69)

 

II

438 (38.05)

402 (38.32)

36 (35.29)

 

III

280 (24.33)

265 (25.26)

15 (14.71)

 

IV

259 (22.50)

224 (21.35)

35 (34.31)

 

HER-2

   

0.055

Positive, n (%)

510 (44.31)

474 (45.19)

36 (35.29)

 

Negative, n (%)

641 (55.69)

575 (54.81)

66 (64.71)

 

Chemotherapy equivalent dose, mg/m2

307.48 ± 11.06

306.73 ± 10.65

307.08 ± 10.08

0.750

Epirubicin, n (%)

645 (56.04)

569 (54.24)

76 (74.51)

 

Pirarubicin, n (%)

506 (43.96)

480 (45.76)

26 (25.49)

 

Hematocrit (%)

39.26 ± 3.14

39.27 ± 3.15

39.11 ± 3.03

0.609

LVEF by 2DE, %

65.85 ± 2.72

65.88 ± 2.65

65.57 ± 3.28

0.277

  1. TG, triglyceride; TC, cholesterol; HDL, high-density lipoprotein; LDL, low density lipoprotein; ALT, alanine transaminase; AST, glutamic oxalacetic transaminase; FBG, fasting blood-glucose; LVEF, left ventricular ejection fraction; 2DE, 2-dimensional echocardiography
  2. p: p value between group CTRCD (−) and CTRCD (+)
Back to article page